Investigation of the Expression of CYP3A4 in Diabetic Rats in Xenobiotic Metabolism

Area of Science:

• Pharmacology
• Biochemistry
• Metabolism

Background:

• Cytochrome P450 3A4 (CYP3A4) is a key enzyme in drug metabolism.
• Diabetes and high-fat diets can alter drug-metabolizing enzyme activity.
• Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used to treat type 2 diabetes.

Purpose of the Study:

• To investigate the effect of dapagliflozin on hepatic CYP3A4 protein expression in a rat model.
• To determine if diabetes influences dapagliflozin's impact on CYP3A4 levels.

Main Methods:

• Male Sprague-Dawley rats were assigned to four groups: control, high-fat diet and streptozotocin (STZ)-induced diabetes, dapagliflozin-treated control, and dapagliflozin-treated diabetes.
• Hepatic microsomes were isolated from rat livers.
• CYP3A4 protein expression was quantified using Western blotting.

Main Results:

• Dapagliflozin treatment significantly decreased hepatic CYP3A4 protein expression in control rats.
• In diabetic rats, dapagliflozin also decreased hepatic CYP3A4 protein expression compared to control and diabetic groups, though not significantly.
• Overall, dapagliflozin demonstrated an inhibitory effect on hepatic CYP3A4 protein levels.

Conclusions:

• Dapagliflozin inhibits hepatic CYP3A4 protein expression.
• This finding has implications for potential drug-drug interactions when dapagliflozin is co-administered with CYP3A4 substrates.